• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    N2OFF Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    3/20/25 9:00:09 AM ET
    $NITO
    Agricultural Chemicals
    Industrials
    Get the next $NITO alert in real time by email
    false 0001789192 0001789192 2025-03-19 2025-03-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 19, 2025

     

    N2OFF, Inc.

    (Exact name of registrant as specified in its charter)

     

    Nevada   001-40403   26-4684680

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    HaPardes 134 (Meshek Sander)

    Neve Yarak, Israel

      4994500
    (Address of principal executive offices)   (Zip Code)

     

    (347) 468- 9583

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of exchange on which registered
    Common Stock, par value $0.0001 per share   NITO   The Nasdaq Capital Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Agreement

     

    As previously disclosed in the Current Report on Form 8-K filed by N2OFF, Inc. (the “Company”) with the Securities and Exchange Commission on December 10, 2024, the Company entered into the Securities Purchase Agreement (the “Agreement”) on December 10, 2024 with certain investors for aggregate gross proceeds of approximately $1,500,000 (the “Private Placement”). As part of the Private Placement, the Company issued an aggregate amount of 6,250,000 units and pre-funded units (collectively, the “Units”) at a purchase price of $0.24 per unit (less $0.00001 per pre-funded unit). Each Unit consisted of (i) one share of common stock, par value $0.0001 per share (the “Common Stock”) and/or one and a half pre-funded warrant to purchase one share of Common Stock (the “Pre-Funded Warrant”), and (ii) a one and a half warrant to purchase one share of Common Stock (the “Common Warrant” and together with the Pre-Funded Warrants, the “Warrants”).

     

    The Agreement and Warrants provided for a beneficial ownership limitation of 4.99% of the Company’s outstanding capital stock (the “Beneficial Ownership Limitation”). On March 19, 2025, the Agreement was amended to change the Beneficial Ownership Limitation applicable to the Agreement and Warrants from 4.99% to 9.99% of the Company’s outstanding capital stock (the “Amendment”). All of the other terms and conditions of the Agreement remain in full force and effect.

     

    The description of the Amendment set forth above is qualified in its entirety by reference to the full text of the Amendment, which is filed hereto as Exhibits 10.1, and incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
         
    10.1   Amendment to the Securities Purchase Agreement, dated March 19, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      N2OFF, Inc.
         
    Date: March 20, 2025 By: /s/ David Palach
      Name: David Palach
      Title: Chief Executive Officer

     

     

    Get the next $NITO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NITO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NITO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Palach David was granted 100,000 units of Restricted Shares of Common Stock (SEC Form 4)

    4 - N2OFF, Inc. (0001789192) (Issuer)

    2/11/26 4:05:31 PM ET
    $NITO
    Agricultural Chemicals
    Industrials

    Controller Zakai Shlomo was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)

    4 - N2OFF, Inc. (0001789192) (Issuer)

    2/11/26 4:05:36 PM ET
    $NITO
    Agricultural Chemicals
    Industrials

    Director Weiss Amitay was granted 116,286 units of Restricted Shares of Common Stock (SEC Form 4)

    4 - N2OFF, Inc. (0001789192) (Issuer)

    2/11/26 4:05:33 PM ET
    $NITO
    Agricultural Chemicals
    Industrials

    $NITO
    SEC Filings

    View All

    N2OFF Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - N2OFF, Inc. (0001789192) (Filer)

    1/13/26 4:05:53 PM ET
    $NITO
    Agricultural Chemicals
    Industrials

    N2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - N2OFF, Inc. (0001789192) (Filer)

    1/12/26 9:15:22 AM ET
    $NITO
    Agricultural Chemicals
    Industrials

    N2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Submission of Matters to a Vote of Security Holders

    8-K - N2OFF, Inc. (0001789192) (Filer)

    12/16/25 4:05:32 PM ET
    $NITO
    Agricultural Chemicals
    Industrials

    $NITO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases

    MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030 Neve Yarak, Israel, Feb. 12, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced that MitoCareX Bio Ltd. ("MitoCareX Bio"), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has shown preliminary in vitro data demonstrating inhibition of pro‑infl

    2/12/26 7:25:00 AM ET
    $NITO
    Agricultural Chemicals
    Industrials

    In Spaceflight Conditions: N2OFF's MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions

    Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. ("MitoCareX Bio"), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induce

    2/2/26 8:05:00 AM ET
    $NITO
    Agricultural Chemicals
    Industrials

    N2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform

    MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030 Neve Yarak, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today announced that MitoCareX Bio Ltd. ("MitoCareX Bio"), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has shown preliminary in vitro data demonstrating inhibition of pro‑inflamm

    1/22/26 7:32:00 AM ET
    $NITO
    Agricultural Chemicals
    Industrials

    $NITO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rosenbloom Ronen bought 50,000 units of Restricted Shares of Common Stock, increasing direct ownership by 345% to 64,500 units (SEC Form 4)

    4 - N2OFF, Inc. (0001789192) (Issuer)

    12/26/24 7:42:11 AM ET
    $NITO
    Agricultural Chemicals
    Industrials

    $NITO
    Financials

    Live finance-specific insights

    View All

    N2OFF Announces Strategic Initiatives Intended to Maximize Shareholder Value

    Neve Yarak, Israel, Oct. 02, 2024 (GLOBE NEWSWIRE) -- N2OFF, Inc.\ (NASDAQ:NITO) (FSE:80W) ("N2OFF" or the "Company"), a clean tech company engaged in sustainable solutions for the energy and agri-tech industries, announced today key strategic initiatives approved by its board of directors (the "Board") that are intended to increase shareholder value. Key Highlights of the Board's Initiatives Spin-off of cleantech activities: N2OFF is considering pursuing a potential spin-off of its cleantech operations - NTWO OFF Ltd. and Save Foods Ltd. – into a separate publicly traded company with the intention of listing that spin-off company on a national exchange. In connection with the potential

    10/2/24 8:30:00 AM ET
    $NITO
    Agricultural Chemicals
    Industrials